Ohnmar Zaw, Nang Noon Shean Aye, Paweena Tunakhun, Jureerut Daduang, Sakda Daduang, Pornsuda Maraming
{"title":"Effect of DNA Aptamer Concentration on the Stability of PDA Nanoparticle-based Electrochemical Biosensor to Detect Glycated Albumin.","authors":"Ohnmar Zaw, Nang Noon Shean Aye, Paweena Tunakhun, Jureerut Daduang, Sakda Daduang, Pornsuda Maraming","doi":"10.21873/invivo.13945","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>The glycated albumin (GA), a potential biomarker for monitoring diabetes mellitus, reflects short-term glycemia and is not influenced by conditions that falsely alter hemoglobin A1c (HbA1c) levels. This study presents a comprehensive evaluation of DNA aptamer-functionalized polydopamine nanoparticles (PDA NPs) for developing a stable biosensor targeting GA.</p><p><strong>Materials and methods: </strong>DNA aptamers, conjugated to PDA NPs at varying aptamer concentrations (0.05, 0.5, and 5 μM), were systematically analyzed to understand their impact on the morphological, electrochemical behavior, and stable responses of the biosensor.</p><p><strong>Results: </strong>Morphological assessments using transmission electron microscopy, scanning electron microscopy, and atomic force microscopy confirmed the stability of PDA NPs after conjugation with aptamers. Electrochemical characterization demonstrated enhanced electron transfer efficiency at an optimal aptamer concentration (0.5 μM) for GA detection while stability testing over 30 days indicated sustained sensor functionality.</p><p><strong>Conclusion: </strong>The PDA-0.5 μM aptamer conjugations balance structural integrity, and stability, emphasizing the importance of aptamer concentration optimization for practical biosensor applications.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1440-1452"},"PeriodicalIF":1.8000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041966/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"In vivo","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/invivo.13945","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background/aim: The glycated albumin (GA), a potential biomarker for monitoring diabetes mellitus, reflects short-term glycemia and is not influenced by conditions that falsely alter hemoglobin A1c (HbA1c) levels. This study presents a comprehensive evaluation of DNA aptamer-functionalized polydopamine nanoparticles (PDA NPs) for developing a stable biosensor targeting GA.
Materials and methods: DNA aptamers, conjugated to PDA NPs at varying aptamer concentrations (0.05, 0.5, and 5 μM), were systematically analyzed to understand their impact on the morphological, electrochemical behavior, and stable responses of the biosensor.
Results: Morphological assessments using transmission electron microscopy, scanning electron microscopy, and atomic force microscopy confirmed the stability of PDA NPs after conjugation with aptamers. Electrochemical characterization demonstrated enhanced electron transfer efficiency at an optimal aptamer concentration (0.5 μM) for GA detection while stability testing over 30 days indicated sustained sensor functionality.
Conclusion: The PDA-0.5 μM aptamer conjugations balance structural integrity, and stability, emphasizing the importance of aptamer concentration optimization for practical biosensor applications.
期刊介绍:
IN VIVO is an international peer-reviewed journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of physiology, pathology and disease management.
The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis.